Joshua Armenia, PhD, of Memorial Sloan Kettering Cancer Center, discusses new information that is changing the understanding of prostate cancer, including the identification of a new subclass, which represents 21% of cases, and the discovery of recurrently mutated cancer pathways not previously implicated in prostate cancer (Abstract 131).
Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract 434)
Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he co-chaired, which included discussion of Canadian vs U.S. guidelines; ProtecT; genomic and hereditary tests; and imaging to guide active surveillance. (General Session 1)
Roland Seiler, MD, of the University of British Columbia, discusses a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses a single-arm biomarker-based study of savolitinib in patients with advanced papillary renal cell cancer. (Abstract 436)
